The Committee for Medicinal Products for Human Use, or CHMP, is recommending that Aduhelm (aducanumab) should not be approved…
Articles by Marisa Wexler, MS
A European Medicines Agency (EMA) committee has voted against approving Biogen’s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease.
A biological framework called the “microcompetition model” may explain why people infected with herpes simplex 1 (HSV1) are at increased…
After reviewing interim trial data, an independent safety board has recommended that Anavex Life Sciences continues a trial, without…
Treatment with the investigational anti-tau monoclonal antibody semorinemab significantly slowed decline in a measure of cognition among people with mild-to-moderate…
Federal lawmakers are asking the U.S. Food and Drug Administration (FDA) to provide additional data and documents related to the…
Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people…
Treatment with Aduhelm (aducanumab) slows the clinical decline observed in in Alzheimer’s across a range of cognitive and functional…
In clinical trials of the Alzheimer’s treatment Aduhelm (aducanumab), participants who experienced a greater reduction in brain levels of…
A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for…